全文获取类型
收费全文 | 11404篇 |
免费 | 810篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 102篇 |
儿科学 | 303篇 |
妇产科学 | 186篇 |
基础医学 | 1300篇 |
口腔科学 | 374篇 |
临床医学 | 1059篇 |
内科学 | 2350篇 |
皮肤病学 | 372篇 |
神经病学 | 1193篇 |
特种医学 | 441篇 |
外科学 | 1744篇 |
综合类 | 130篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 881篇 |
眼科学 | 257篇 |
药学 | 670篇 |
中国医学 | 12篇 |
肿瘤学 | 879篇 |
出版年
2021年 | 172篇 |
2020年 | 128篇 |
2019年 | 198篇 |
2018年 | 208篇 |
2017年 | 146篇 |
2016年 | 152篇 |
2015年 | 183篇 |
2014年 | 275篇 |
2013年 | 478篇 |
2012年 | 664篇 |
2011年 | 692篇 |
2010年 | 389篇 |
2009年 | 397篇 |
2008年 | 698篇 |
2007年 | 729篇 |
2006年 | 706篇 |
2005年 | 697篇 |
2004年 | 652篇 |
2003年 | 627篇 |
2002年 | 584篇 |
2001年 | 187篇 |
2000年 | 163篇 |
1999年 | 173篇 |
1998年 | 133篇 |
1997年 | 116篇 |
1996年 | 108篇 |
1995年 | 94篇 |
1994年 | 87篇 |
1993年 | 84篇 |
1992年 | 99篇 |
1991年 | 95篇 |
1990年 | 106篇 |
1989年 | 114篇 |
1988年 | 100篇 |
1987年 | 92篇 |
1986年 | 91篇 |
1985年 | 81篇 |
1984年 | 80篇 |
1983年 | 90篇 |
1982年 | 90篇 |
1981年 | 96篇 |
1980年 | 81篇 |
1979年 | 87篇 |
1978年 | 59篇 |
1977年 | 74篇 |
1976年 | 77篇 |
1975年 | 64篇 |
1974年 | 54篇 |
1973年 | 41篇 |
1972年 | 45篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
2.
3.
4.
5.
Theodore M. Brasky Roberta M. Ray Sandi L. Navarro Jeannette M. Schenk Alison M. Newton Marian L. Neuhouser 《International journal of cancer. Journal international du cancer》2020,147(5):1374-1384
We and others have reported associations between B vitamins principally involved in one-carbon metabolism and increased lung cancer risk; however, results for women have been inconsistent. Here we report on the association of supplemental vitamins B6, folic acid and B12 intake and lung cancer risk using data from the Women's Health Initiative (WHI) study of postmenopausal women. Between 1993 and 1998, 161,808 women were recruited to participate in the WHI at 40 clinical centers in the US. After exclusions, 159,232 women were available for analysis and followed prospectively for an average of 18.3 years. Among them, 3,836 incident lung cancer cases were diagnosed. At baseline, supplemental B vitamins from multivitamins, vitamin mixtures and individual supplements were assessed. Adjusted Cox regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between supplemental B vitamin intake and lung cancer risk. Relative to no intake, women who took ≥50 mg/day of vitamin B6 had 16% (HR 0.84, 95% CI: 0.71–0.99) reduced lung cancer risk. Associations did not differ significantly by smoking status or lung cancer histology. Intakes of folic acid and vitamin B12 were not associated with risk. There is a need for replication of our findings from other large, prospective studies with similar high-quality measurement of supplement intakes before any recommendations can be made at present on B6 supplementation for lung cancer prevention in women. 相似文献
6.
7.
L. Misery E. Weisshaar E. Brenaut A.W.M. Evers F. Huet S. Ständer A. Reich E. Berardesca E. Serra-Baldrich J. Wallengren D. Linder J.W. Fluhr J.C. Szepietowski H. Maibach for the Special Interest Group on sensitive skin of the International Forum for the Study of Itch 《Journal of the European Academy of Dermatology and Venereology》2020,34(2):222-229
The special interest group on sensitive skin of the International Forum for the Study of Itch previously defined sensitive skin as a syndrome defined by the occurrence of unpleasant sensations (stinging, burning, pain, pruritus and tingling sensations) in response to stimuli that normally should not provoke such sensations. This additional paper focuses on the pathophysiology and the management of sensitive skin. Sensitive skin is not an immunological disorder but is related to alterations of the skin nervous system. Skin barrier abnormalities are frequently associated, but there is no cause and direct relationship. Further studies are needed to better understand the pathophysiology of sensitive skin – as well as the inducing factors. Avoidance of possible triggering factors and the use of well-tolerated cosmetics, especially those containing inhibitors of unpleasant sensations, might be suggested for patients with sensitive skin. The role of psychosocial factors, such as stress or negative expectations, might be relevant for subgroups of patients. To date, there is no clinical trial supporting the use of topical or systemic drugs in sensitive skin. The published data are not sufficient to reach a consensus on sensitive skin management. In general, patients with sensitive skin require a personalized approach, taking into account various biomedical, neural and psychosocial factors affecting sensitive skin. 相似文献
8.
9.
A. Nast C. Smith P.I. Spuls G. Avila Valle Z. Bata-Csörgö H. Boonen E. De Jong I. Garcia-Doval P. Gisondi D. Kaur-Knudsen S. Mahil T. Mälkönen J.T. Maul S. Mburu U. Mrowietz K. Reich E. Remenyik K.M. Rønholt P.G. Sator M. Schmitt-Egenolf M. Sikora K. Strömer O. Sundnes D. Trigos G. Van Der Kraaij N. Yawalkar C. Dressler 《Journal of the European Academy of Dermatology and Venereology》2020,34(11):2461-2498
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab. 相似文献
10.
Theodore C. Bania MD MS Tom Ashar MD Gregory Press MD Patricia M. Carey MD 《Academic emergency medicine》2003,10(7):697-704
Long-term daily use of gamma-hydroxybutyrate (GHB) and related compounds has recently been associated with a withdrawal syndrome. To the best of the authors' knowledge, there are currently no animal models of GHB withdrawal. OBJECTIVES: The authors studied and described the effect of chronic dosing of GHB (3-6 days) on tolerance and withdrawal in a rat model. METHODS: Rats were administered GHB every three hours via intraperitoneal catheter. Groups of rats (2 per group) were dosed with GHB for either 3 (24 doses), 4 (32 doses), 5 (40 doses), or 6 (48 doses) days. The GHB dose was 0.25 g/kg for doses 1-8, 0.75 g/kg for doses 9-12, 1 g/kg for doses 13-16, 1.25 g/kg for doses 17-24, 1.5 g/kg for doses 25-32, 1.75 g/kg for doses 33-40, and 2 g/kg for doses 41-48. Following the last dose of GHB, the rats were scored using a 16-point ethanol intoxication-withdrawal scale rating spontaneous behaviors, response to handling, grooming, and neurological signs. Lower scores indicate intoxication, while higher scores indicate withdrawal. Scores were recorded at hours 0, 1, 2, 3, 4, 5, 6, 9, 12, and 24. RESULTS: Tolerance: Rats dosed with GHB for more days were less intoxicated one hour after their last GHB dose despite receiving higher doses. WITHDRAWAL: The scores for all rats dosed with GHB increased at hours 4 (p = 0.028), 5 (p = 0.037), 6 (p = 0.007), and 9 (p = 0.024) after the last dose, indicating withdrawal. The scores demonstrated a linear increase dependent upon the number of days of GHB dosing at hours 3 (p < 0.000), 4 (p = 0.004), 5 (p = 0.002), and 12 (p = 0.039) as well as prior to the last dose at hour 0 (p = 0.000). No rats developed seizures. CONCLUSIONS: Tolerance and mild withdrawal in rats can be induced by administering intraperitoneal GHB every three hours for 3-6 days. More prolonged dosing and higher doses of GHB may be necessary to induce severe withdrawal. 相似文献